Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (81-90 of 186) with videos related to

Pageof 19
Sort By:
British Journal of Clinical Pharmacology|May 8, 2002
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsRomano Danesi, Federico Innocenti, Stefano Fogli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2016
Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal CancerGiuseppe Toffoli, Manish R Sharma, Elena Marangon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsFederico Innocenti, Deanna L Kroetz, Erin Schuetz, et al.
Journal of the National Cancer Institute|August 8, 2014
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)Katherine Van Loon, Kouros Owzar, Chen Jiang, et al.
Pharmacogenetics and Genomics|July 16, 2008
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 geneFederico Innocenti, Wanqing Liu, Donna Fackenthal, et al.
Plos One|February 6, 2014
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapyValli De Re, Laura Caggiari, Mariangela De Zorzi, et al.
The Pharmacogenomics Journal|December 22, 2021
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitorsJulia C F Quintanilha, Alessandro Racioppi, Jin Wang, et al.
BMC Genomics|June 14, 2013
A genome-wide integrative study of microRNAs in human liverEric R Gamazon, Federico Innocenti, Rongrong Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.
Pharmacogenetics and Genomics|January 21, 2006
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytesJacqueline Ramírez, Bernard J Komoroski, Snezana Mirkov, et al.
Pageof 19

Showing results (81-90 of 186) with videos related to

Sort By:
Pageof 19
British Journal of Clinical Pharmacology|May 8, 2002
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsRomano Danesi, Federico Innocenti, Stefano Fogli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2016
Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal CancerGiuseppe Toffoli, Manish R Sharma, Elena Marangon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsFederico Innocenti, Deanna L Kroetz, Erin Schuetz, et al.
Journal of the National Cancer Institute|August 8, 2014
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)Katherine Van Loon, Kouros Owzar, Chen Jiang, et al.
Pharmacogenetics and Genomics|July 16, 2008
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 geneFederico Innocenti, Wanqing Liu, Donna Fackenthal, et al.
Plos One|February 6, 2014
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapyValli De Re, Laura Caggiari, Mariangela De Zorzi, et al.
The Pharmacogenomics Journal|December 22, 2021
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitorsJulia C F Quintanilha, Alessandro Racioppi, Jin Wang, et al.
BMC Genomics|June 14, 2013
A genome-wide integrative study of microRNAs in human liverEric R Gamazon, Federico Innocenti, Rongrong Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.
Pharmacogenetics and Genomics|January 21, 2006
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytesJacqueline Ramírez, Bernard J Komoroski, Snezana Mirkov, et al.
Pageof 19